Role of recombinant human brain natriuretic peptide combined with sodium nitroprusside in improving quality of life and cardiac function in patients with acute heart failure

Peng,Yang; Wei,Han

doi:10.3892/etm.2020.8667

Role of recombinant human brain natriuretic peptide combined with sodium nitroprusside in improving quality of life and cardiac function in patients with acute heart failure

Authors:
- Yang Peng
- Han Wei
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China
Published online on: April 15, 2020 https://doi.org/10.3892/etm.2020.8667
Pages: 261-268
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role of recombinant human brain natriuretic peptide (RHBNP) combined with sodium nitroprusside (SN) in improving quality of life and cardiac function in patients with acute heart failure. A total of 96 patients with acute heart failure who were admitted to The First Affiliated Hospital of Yangtze University were included in the current study. A total of 48 patients were treated with RHBNP combined with SN (research group) and 48 patients were treated with SN alone (control group). To assess the efficacy and safety of the two treatments, the study groups were compared in terms of improvement in clinical symptoms and cardiac function indices, including pulmonary capillary wedge pressure and left ventricular ejection fraction, which was measured using a non‑invasive cardiac hemodynamic detector; changes in fluid intake and 24 h urine volumes after drug use; cardiac function classification before treatment and three days after treatment; adverse drug reactions during treatment and mortality within 1 month of treatment. Following treatment, compared with the control group, the research group demonstrated significantly higher fluid intake and 24 h urine volume after drug use, improved cardiac function indices, cardiac function classification, biochemical indicators and total effective rate of treatment (all P<0.05); significantly lower total incidence of adverse reactions (P<0.05) and similar mortality within 1 month of treatment. With improvements in cardiac and other organ function, RHBNP combined with SN was found to be effective in the treatment of acute heart failure. RHBNP can effectively promote urination, reduce inflammatory responses and rapidly relieve clinical symptoms without significant adverse reactions, indicating its potential use in further clinical application.

View Figures

View References

1	Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, et al: Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 17:544–558. 2015.PubMed/NCBI View Article : Google Scholar
2	Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, Okumura T, Kida K, Mizuno A, Oishi S, et al: Time-to-Furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 69:3042–3051. 2017.PubMed/NCBI View Article : Google Scholar
3	Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, et al: Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC Heart Failure Long-term registry. Eur J Heart Fail. 19:1242–1254. 2017.PubMed/NCBI View Article : Google Scholar
4	Maaten JMT, Valente MAE, Damman K, Hillege HL, Navis G and Voors AA: Diuretic response in acute heart failure[mdash]pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 12(184)2015.PubMed/NCBI View Article : Google Scholar
5	Xu H, Wang B, Meng Q, Li J, Sun W, Xin L and Chen L: Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure. Pak J Med Sci. 33:540–544. 2017.PubMed/NCBI View Article : Google Scholar
6	Yu L, Shi X, Han C, Rao C and Wang J: A rapid reporter assay for recombinant human brain natriuretic peptide (rhBNP) by GloSensor technology. J Pharm Anal. 8:297–301. 2018.PubMed/NCBI View Article : Google Scholar
7	Zhang S and Wang Z: Effect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failure: A systematic review and meta-analysis. Medicine (Baltimore). 95(e4757)2016.PubMed/NCBI View Article : Google Scholar
8	Su Z, Wei G, Wei L, Liu J and Li X: Effects of rhBNP on myocardial fibrosis after myocardial infarction in rats. Int J Clin Exp Pathol. 8:6407–6415. 2015.PubMed/NCBI
9	Cruz JE, Thomas Z, Lee D, Moskowitz DM and Nemeth J: Therapeutic interchange of clevidipine for sodium nitroprusside in cardiac surgery. P T. 41:635–639. 2016.PubMed/NCBI
10	Olesen ND, Fischer M and Secher NH: Sodium nitroprusside dilates cerebral vessels and enhances internal carotid artery flow in young men. J Physiol. 596:3967–3976. 2018.PubMed/NCBI View Article : Google Scholar
11	Fisher JD: New York Heart Association classification. Arch Intern Med. 129(836)1972.PubMed/NCBI
12	Chiem AT, Chan CH, Ander DS, Kobylivker AN and Manson WC: Comparison of expert and novice sonographers' performance in focused lung ultrasonography in dyspnea (FLUID) to diagnose patients with acute heart failure syndrome. Acad Emerg Med. 22:564–573. 2015.PubMed/NCBI View Article : Google Scholar
13	Bredy C, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Diller GP, Gatzoulis MA and Dimopoulos K: New York Heart Association (NYHA) classification in adults with congenital heart disease: Relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes. 4:51–58. 2018.PubMed/NCBI View Article : Google Scholar
14	Kaski JC: Cardiac Syndrome X and Microvascular Angina, 1999.
15	Ziaeian B and Fonarow GC: Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 13:368–378. 2016.PubMed/NCBI View Article : Google Scholar
16	Sinnenberg L and Givertz MM: Acute heart failure. Trends Cardiovasc Med. 30:104–112. 2019.PubMed/NCBI View Article : Google Scholar
17	Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, et al: Organ dysfunction, injury and failure in acute heart failure: From pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 19:821–836. 2017.PubMed/NCBI View Article : Google Scholar
18	Kastl SP, Krychtiuk KA, Lenz M, Distelmaier K, Goliasch G, Huber K, Wojta J, Heinz G and Speidl WS: Intestinal fatty acid binding protein is associated with mortality in patients with acute heart failure or cardiogenic shock. Shock. 51:410–415. 2019.PubMed/NCBI View Article : Google Scholar
19	Harjola VP, Parissis J, Brunner-La Rocca HP, Čelutkienė J, Chioncel O, Collins SP, De Backer D, Filippatos GS, Gayat E, Hill L, et al: Comprehensive in-hospital monitoring in acute heart failure: Applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 20:1081–1099. 2018.PubMed/NCBI View Article : Google Scholar
20	He XM, Chen L, Luo JB, Feng XX, Zhang YB, Chen QJ, Ji XL and Wang TS: Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. Asian Pac J Trop Med. 9:791–795. 2016.PubMed/NCBI View Article : Google Scholar
21	Hua P, Liu J, Tao J, Lin X, Zou R, Zhang D and Yang S: Safety and efficacy of the perioperative administration of recombinant human brain natriuretic peptide (rhBNP): A systematic review and meta-analysis. Ther Clin Risk Manag. 14:313–321. 2018.PubMed/NCBI View Article : Google Scholar
22	Farooq A, Whitehead D and Azzawi M: Attenuation of endothelial-dependent vasodilator responses, induced by dye-encapsulated silica nanoparticles, in aortic vessels. Nanomedicine (Lond). 9:413–425. 2014.PubMed/NCBI View Article : Google Scholar
23	Fida TT, Voordouw J, Ataeian M, Kleiner M, Okpala G, Mand J and Voordouw G: Synergy of sodium nitroprusside and nitrate in inhibiting the activity of sulfate reducing bacteria in Oil-containing bioreactors. Front Microbiol. 9(981)2018.PubMed/NCBI View Article : Google Scholar
24	Wei X, Yan T, Dai H and Wei Z: Clinical efficacy of rhBNP in treating AHF and its effect on hemodynamics and inflammatory factors. Chongqing Med. 27:2017.(In Chinese).
25	Guiha NH, Cohn JN, Mikulic E, Franciosa JA and Limas CJ: Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med. 291:587–592. 1974.PubMed/NCBI View Article : Google Scholar
26	Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO and Tang WH: Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 52:200–207. 2008.PubMed/NCBI View Article : Google Scholar
27	Strassheim D, Dempsey EC, Gerasimovskaya E, Stenmark K and Karoor V: Role of inflammatory cell subtypes in heart failure. J Immunol Res. 2019:1–9. 2019.PubMed/NCBI View Article : Google Scholar
28	Apple FS, Steffen LM, Pearce LA, Murakami MM and Luepker RV: Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: The Minnesota Heart Survey. Clin Chem. 58:930–935. 2012.PubMed/NCBI View Article : Google Scholar